Brief: Aerovate Therapeutics Announces Results From Phase 2 Trial Evaluating AV-101 For Pulmonary Arterial Hypertension

Jade Biosciences

17/06/2024 13:51

June 17 (Reuters) - Aerovate Therapeutics Inc  AVTE.O :
    * AEROVATE THERAPEUTICS ANNOUNCES 24-WEEK TOPLINE RESULTS
FROM THE
PHASE 2B PORTION OF IMPAHCT EVALUATING AV-101 FOR THE TREATMENT
OF PULMONARY ARTERIAL HYPERTENSION
    * AEROVATE HALTS PHASE 3 OF IMPAHCT TRIAL
    * AEROVATE THERAPEUTICS INC: PRIMARY ENDPOINT FOR PHASE 2B
PORTION
OF IMPAHCT IS CHANGE IN PVR COMPARED WITH PLACEBO
    * AEROVATE THERAPEUTICS INC: STUDY DID NOT MEET ITS PRIMARY
ENDPOINT
    * AEROVATE THERAPEUTICS INC: STUDY DID NO SHOW MEANINGFUL
IMPROVEMENTS IN SECONDARY ENDPOINT OF CHANGE IN SIX MINUTE WALK
DISTANCE
    * AEROVATE THERAPEUTICS INC: PLANS TO RELEASE FULL DATA FROM
PHASE
2B PORTION OF IMPAHCT AT A LATER DATE, TIMING OF WHICH IS TO BE
DETERMINED

Source text for Eikon:  ID:nGNX8tks7m 
Further company coverage:  AVTE.O 

 ((Reuters.Briefs@thomsonreuters.com;))